tirzepatide chronic kidney disease (Zepbound) showed improved function in obese patients with both kidney and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https A comparison of the effects

It is a synthetic derivative closely resembling a sequence found in human gastric juice

The weight regain reality Clinical data shows that patients who discontinue semaglutide regain approximately two-thirds of their lost weight within one year

This can manifest as generalised aches, particularly in weight-bearing joints such as the knees, hips, and lower back

This trial will be the definitive test of whether retatrutide's superior metabolic effects translate into superior cardiovascular event reduction, or whether the incremental benefit of the glucagon component is captured in surrogate endpoints without extending to hard clinical outcomes

Additional trials have shown this medication is twice as effective as Semaglutide 1.0mg